Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Experts discuss patient-reported outcomes from the TiNivo-2 trial, focusing on quality of life and the treatment experience.